BioCentury | Jan 30, 2021
Deals

Catabasis reboots with takeout of Xontogeny’s Quellis; plus Merck-Artiva, Lilly-Asahi, Medigene, Xuanzhu-Combio, Bellicum

...lone asset failed in Phase III testing, Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) is acquiring Xontogeny portfolio company Quellis Biosciences Inc....
...treated metastatic pancreatic or prostate cancer.TARGETSP2RX7 (P2X7) – Purinergic receptor P2X ligand-gated ion channel 7 BC Staff Quellis Biosciences Inc. Eli...
BioCentury | Dec 10, 2019
Finance

Perceptive launches $210M early-stage fund tied to Garabedian’s accelerator Xontogeny

...”). PXV closed earlier this week, but it has already invested in two therapeutics companies: Quellis Biosciences Inc....
...corporate development at Gilead Sciences Inc. (NASDAQ:GILD). Val Kennedy, Associate Editor Perceptive Advisors Landos Biopharma Inc. Morphiex Biotherapeutics Inc. Xontogeny LLC Quellis Biosciences Inc....
Items per page:
1 - 2 of 2
BioCentury | Jan 30, 2021
Deals

Catabasis reboots with takeout of Xontogeny’s Quellis; plus Merck-Artiva, Lilly-Asahi, Medigene, Xuanzhu-Combio, Bellicum

...lone asset failed in Phase III testing, Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) is acquiring Xontogeny portfolio company Quellis Biosciences Inc....
...treated metastatic pancreatic or prostate cancer.TARGETSP2RX7 (P2X7) – Purinergic receptor P2X ligand-gated ion channel 7 BC Staff Quellis Biosciences Inc. Eli...
BioCentury | Dec 10, 2019
Finance

Perceptive launches $210M early-stage fund tied to Garabedian’s accelerator Xontogeny

...”). PXV closed earlier this week, but it has already invested in two therapeutics companies: Quellis Biosciences Inc....
...corporate development at Gilead Sciences Inc. (NASDAQ:GILD). Val Kennedy, Associate Editor Perceptive Advisors Landos Biopharma Inc. Morphiex Biotherapeutics Inc. Xontogeny LLC Quellis Biosciences Inc....
Items per page:
1 - 2 of 2